Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region for Merck Biopharma Global Commercial Operations, Chris Round, outlines what practical steps the ...

Merck (MRK) says it Capvaxive vaccine showed positive immune responses in a Phase 3 trial for adults at risk for pneumonia.

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab, marketed ...